Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Neonatal Outcomes Among Patients Undergoing Intravenous Glucose Tolerance Testing for Screening of Gestational Diabetes
NNeeoonnaattaall OOuuttccoommeess AAmmoonngg PPaattiieennttss UUnnddeerrggooiinngg IInnttrraavveennoouuss GGlluuccoossee TToolleerraannccee TTeessttiinngg ffoorr SSccrreeeenniinngg ooff GGeessttaattiioonnaall DDiiaabbeetteess

Neonatal Outcomes Among Patients Undergoing Intravenous Glucose Tolerance Testing for Screening of Gestational Diabetes

R I Med J (2013). 2025 Jan 2;108(1):13-18.

ABSTRACT

BACKGROUND: Despite the prevalence and associated maternal and neonatal morbidities of gestational diabetes (GDM), there is no consensus regarding an alternative test for patients who cannot tolerate the oral glucose tolerance test (OGTT).

OBJECTIVE(S): To assess neonatal outcomes among patients undergoing an intravenous glucose tolerance test (IV GTT) to screen for GDM when an OGTT could not be tolerated.

STUDY DESIGN: Prospective cohort study which enrolled patients intolerant of OGTT between February 2019 to February 2020. All participants underwent an IV GTT and glucose monitoring was initiated if the glucose metabolism rate was abnormal based on trimester-specific cut-offs. 111 participants were needed to detect a 25% difference in the rate of large for gestational age (LGA) infants between patients with a normal compared to those with an abnormal IV GTT result.

RESULTS: Of the 115 participants who completed glucose testing, 13 (11.3%) had abnormal results. Patient characteristics were similar between those with normal and abnormal test results, with the exception that abnormal results were more common in twin gestation. Maternal outcomes were similar between the two groups. Neonatal complications differed between groups; patients with an abnormal IV GTT result were more likely to have LGA neonates (23.1% vs 3.1%, p=0.02) and lower mean neonatal blood glucose nadirs (36.8 mg/dL vs 48.2 mg/dL, p=0.04).

CONCLUSION(S): An abnormal IV GTT result was associated with clinically significant neonatal morbidities commonly associated with GDM. The IV GTT is a reasonable alternative screening test for GDM related neonatal complications when an OGTT cannot be tolerated.

PMID:39693529